Trial0
Sign inMap the options

Clinical trial · NCT07167966

Alzheimer's Tau Platform: Regimen A - AADvac1

Enrolling by invitationPhase 2

Sponsor: Paul S. Aisen

Request access helpRegistry record ↗

We save this real registry record and notify you if its published status changes. Create an account to add profile details that improve future matching.

Summary

The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. Regimen A will evaluate the safety and efficacy of AADvac1, alone or in combination with donanemab.

Interventions

  • AADvac1 · DRUG

    Subcutaneous injection of AADvac1

  • Donanemab · DRUG

    Active comparator: intravenous infusion of donanemab

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT06957418).

Exclusion Criteria:

* No additional exclusion criteria beyond the exclusion criteria specified in the Master Protocol (NCT06957418).

Sites (3)

  • University of California, San Francisco (UCSF), Memory and Aging Center, San Francisco, California
  • Butler Hospital Memory and Aging Program, Providence, Rhode Island
  • Vanderbilt University Medical Center, Nashville, Tennessee

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2026-09-08.